Condoliase is a Recombinant Enzyme owned by Seikagaku, and is involved in 10 clinical trials, of which 7 were completed, and 3 are ongoing.

Condoliase (SI-6603) is a musculoskeletal system agent which specifically degrades glycosaminoglycans. It dissolves/degrades chondroitin sulfate, dermatan sulfate and hyaluronic acid. Its specificity is quite high. It works without negatively affecting surrounding tissues or organs of the disc, such as blood vessels and nerves. With a single injection into the herniated disc, it degrades GAGs, the principal component of the nucleus pulposus. As a result, the internal pressure is reduced and the herniated nucleus pulposus recedes, bringing expected alleviation of the pain and numbness. SI-6603 could be effective for the treatment of lumbar disc herniation.

The revenue for Condoliase is expected to reach a total of $303m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Condoliase NPV Report.

Condoliase is originated and owned by Seikagaku. Kaken Pharmaceutical is the other company associated in development or marketing of Condoliase.

Condoliase Overview

Condoliase (Hernicore/ SI-6603) is an recombinant enzyme, a formulation of chondroitinase ABC produced from bacteria. It is formulated as injectable solution for intradiscal route of administration. It is indicated for the treatment of lumbar disc herniation in adults. It is under development for the treatment of lumbar disc herniation.

Kaken Pharmaceutical Overview

Kaken Pharmaceutical (Kaken) is a specialty pharmaceutical company that conducts research and development of drugs, agrochemicals and medical equipments. The company offers solutions in the fields of orthopedics, dermatology, immunology, inflammation, allergies, fungal infections and pain relief. Kaken also offers fungicides, rice herbicide, anti-coccidial for chickens and polypeptide antibiotics. The company conducts research in inflammation and immunology, neurological pain relief and fungal infection areas. It markets products through license and distribution agreements with companies in the US, Canada, Taiwan, China, South Korea, Israel and Jordan and operates sales offices in various places in Japan. Kaken is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY76,034 million for the fiscal year ended March 2022 (FY2022), an increase of 1.4% over FY2021. In FY2022, the company’s operating margin was 17.4%, compared to an operating margin of 23.6% in FY2021. In FY2022, the company recorded a net margin of 12.6%, compared to a net margin of 17.9% in FY2021. The company reported revenues of JPY18,622 million for the second quarter ended September 2022, an increase of 2.3% over the previous quarter.

Quick View – Condoliase

Report Segments
  • Innovator (NME)
Drug Name
  • Condoliase
Administration Pathway
  • Intrathecal
Therapeutic Areas
  • Gastrointestinal
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.